ES2566934T3 - Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina - Google Patents

Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina Download PDF

Info

Publication number
ES2566934T3
ES2566934T3 ES11718122.2T ES11718122T ES2566934T3 ES 2566934 T3 ES2566934 T3 ES 2566934T3 ES 11718122 T ES11718122 T ES 11718122T ES 2566934 T3 ES2566934 T3 ES 2566934T3
Authority
ES
Spain
Prior art keywords
treatment
under
retina
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11718122.2T
Other languages
English (en)
Inventor
Francine Behar-Cohen
Nicolette Farman
Frédéric Jaissier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris 5 Rene Descartes filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES2566934T3 publication Critical patent/ES2566934T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un antagonista del receptor de mineralocorticoides (RM) o un inhibidor de la expresión génica del receptor de mineralocorticoides, para su uso en el tratamiento de la acumulación de líquido en y/o bajo la retina asociada con coriorretinitis serosa central.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23

Claims (1)

  1. imagen1
ES11718122.2T 2010-05-10 2011-05-10 Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina Active ES2566934T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US359075P 2002-02-21
EP10305493 2010-05-10
EP10305493 2010-05-10
US35907510P 2010-06-28 2010-06-28
US35957510P 2010-06-29 2010-06-29
US359575P 2010-06-29
PCT/EP2011/057497 WO2011141456A1 (en) 2010-05-10 2011-05-10 Methods and compositions for the treatment of fluid accumulation in and/ or under the retina

Publications (1)

Publication Number Publication Date
ES2566934T3 true ES2566934T3 (es) 2016-04-18

Family

ID=42289485

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15183988.3T Active ES2641144T3 (es) 2010-05-10 2011-05-10 Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
ES11718122.2T Active ES2566934T3 (es) 2010-05-10 2011-05-10 Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15183988.3T Active ES2641144T3 (es) 2010-05-10 2011-05-10 Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina

Country Status (7)

Country Link
US (2) US8957052B2 (es)
EP (3) EP2977084B1 (es)
JP (3) JP6148175B2 (es)
CA (1) CA2796307A1 (es)
ES (2) ES2641144T3 (es)
IL (1) IL222482A0 (es)
WO (1) WO2011141456A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6148175B2 (ja) 2010-05-10 2017-06-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 網膜中および／または網膜下における液体貯留の処置のための方法および組成物
WO2014202744A1 (en) 2013-06-21 2014-12-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
JP6835836B2 (ja) * 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013012A (en) 1960-12-22 1961-12-12 Searle & Co Alkanoylthio-17alpha-carboxyethyl-17beta-hydroxyandrosten-3-one lactones
US3257390A (en) 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE3506100A1 (de) 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
EP0973791B1 (en) 1995-12-11 2007-06-20 G.D. Searle LLC. Process for the preparation of an epoxy compound
BR9714510A (pt) 1996-12-11 2000-11-28 Searle & Co Processo e preparo de esteróides de 9,11-époxi e intermediários úteis dos mesmos
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
MXPA01008056A (es) 1999-12-08 2003-07-21 Pharmacia Corp Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.
EP1175434A2 (en) 1999-12-08 2002-01-30 Pharmacia Corporation Eplerenone crystalline form
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
CN1774251A (zh) * 2001-12-12 2006-05-17 法玛西雅公司 应用环氧甾类醛固酮受体拮抗剂治疗眼病的方法
CA2478172A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US20050143363A1 (en) * 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
BRPI0406883A (pt) 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
US20040213782A1 (en) * 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
US20040171598A1 (en) * 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
WO2004073608A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
EP1699503B8 (en) * 2003-12-24 2012-11-07 Novartis AG Devices coated with PEC polymers
WO2005079781A1 (en) * 2004-02-25 2005-09-01 La Trobe University Therapeutic and/or prophylactic method
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1755616B1 (en) * 2004-04-08 2013-08-14 Advanced Ocular Systems Limited Treatment of exudative retinopathy with mineralcorticoids
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
KR101155288B1 (ko) 2004-07-30 2012-07-02 엑셀리시스, 인코포레이티드 의약제로서의 피롤 유도체
AU2006205220B2 (en) 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
EP1844768A1 (en) 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
PL2089367T3 (pl) 2006-10-31 2012-04-30 Pfizer Prod Inc Związki pirazolinowe jako antagoniści receptora mineralokortykoidowego
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP6148175B2 (ja) 2010-05-10 2017-06-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 網膜中および／または網膜下における液体貯留の処置のための方法および組成物

Also Published As

Publication number Publication date
EP3238781B1 (en) 2019-07-31
IL222482A0 (en) 2012-12-31
EP2568986A1 (en) 2013-03-20
JP2018039824A (ja) 2018-03-15
CA2796307A1 (en) 2011-11-17
EP3238781A1 (en) 2017-11-01
JP6425785B2 (ja) 2018-11-21
EP2977084B1 (en) 2017-07-05
US9610294B2 (en) 2017-04-04
US20150216879A1 (en) 2015-08-06
JP6435283B2 (ja) 2018-12-05
ES2641144T3 (es) 2017-11-07
WO2011141456A1 (en) 2011-11-17
JP2016138116A (ja) 2016-08-04
JP2013528596A (ja) 2013-07-11
EP2568986B1 (en) 2016-01-13
US20130131024A1 (en) 2013-05-23
EP2977084A1 (en) 2016-01-27
US8957052B2 (en) 2015-02-17
JP6148175B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EP3150138A3 (en) Compressible adjunct with intermediate supporting structures
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2014001639A1 (es) Uso simultaneo, separado o secuencial de un agonista de ppar gamma seleccionado del grupo de glitazonas con un activador de nrf2 aislado seleccionado de un grupo especifico o una composicion que lo comprende, para el tratamiento de un trastorno autoinmune y/o inflamatorio; composicion farmaceutica que comprende a dicho agonista de ppar gamma y al activador de nrf2; y kit que la comprende.
MX2017002703A (es) Sondas para la proyección de imagen de la proteína huntingtina.
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
DOP2016000176A (es) Insulina de acción prolongada y uso de la misma
FR3026513B1 (fr) Diagnostic permettant de determiner le bon etat de fonctionnement d'un dispositif de stockage
UY34419A (es) Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo
CR20160061A (es) Formulación estable líquida de etelcalcetide (amg 461)
ES2566934T3 (es) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
ES2482168T3 (es) Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
IT201700081272A1 (it) Indumento per uso in operazioni di spegnimento di incendi e simili
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2478692A1 (es) Formulaciones líquidas de carbocisteína de propiedades mejoradas